TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19336644

Group type: EXPERIMENTAL
Intervention: Magnesium L-lactate (6 tablets daily, 504 mg elemental magnesium)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Magnesium L-lactate
Number of subjects: 50
Study: 17453221

Group type: EXPERIMENTAL
Intervention: Intravaginal non‐moistened (dry) misoprostol (group A, n = 40)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Misoprostol moistened with 3 ml of saline (group B, n = 41)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Comparison of delivery with first dose, delivery within 12 hours, and delivery within 24 hours
Number of subjects: 81
Study: 15215808

Group type: EXPERIMENTAL
Intervention: Risk score developed from significant variables including age >65 years, heart rate >100 beats/min, history of diabetes mellitus, lateral electrocardiographic changes, and history of angiographically confirmed coronary artery disease.
Number of subjects: 4681

Group type: EXPERIMENTAL
Intervention: BNP (B-type natriuretic peptide) added to the risk score.
Number of subjects: 4681
Study: 11332163

Group type: EXPERIMENTAL
Intervention: 0.2 g/kg/d gluten (group A)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg/d gluten (group B)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg/d gluten (group B) after increasing dose from 0.2 g/kg/d
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control for AGA and EmA levels
Number of subjects: 54
Study: 11477861

Group type: EXPERIMENTAL
Intervention: Tongqiao tablet (TQT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 96
Study: 8041413

Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 520

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 520
Study: 2646983

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Chlormethiazole
Number of subjects: 32
Study: 29602750

Group type: EXPERIMENTAL
Intervention: Modified sternal precautions (less restrictive)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual restrictive sternal precautions
Number of subjects: 72
Study: 27167119

Group type: EXPERIMENTAL
Intervention: Brief thermal sensitization (45°C for 3 min)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Heat pain detection threshold
Number of subjects: 50
Study: 26205427

Group type: EXPERIMENTAL
Intervention: Preterm infants (≤34 weeks GA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Term infants (≥38 weeks GA)
Number of subjects: 90
Study: 23547660

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5 μg once daily
Number of subjects: 17000

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 2.5 μg once daily
Number of subjects: 17000

Group type: COMPARATOR
Intervention: Tiotropium HandiHaler 18 μg once daily
Number of subjects: 17000
Study: 21923604

Group type: EXPERIMENTAL
Intervention: Push-pull method of blood sampling from ports
Number of subjects: 62

Group type: COMPARATOR
Intervention: Finger lancet puncture
Number of subjects: 62
Study: 18333940

Group type: EXPERIMENTAL
Intervention: Intrauterine transfusion (IUT) given to all survivors who were anaemic
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Occlusive techniques
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Other management techniques
Number of subjects: 19
Study: 16835556

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0
Study: 12685617

Group type: EXPERIMENTAL
Intervention: Chronic nitrate treatment for 6 months after MI
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no nitrate treatment)
Number of subjects: 59
Study: 10099056

Group type: EXPERIMENTAL
Intervention: Tiazac (240 mg single dose)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cardizem CD (240 mg single dose)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tiazac (240 mg steady-state)
Number of subjects: 23
Study: 7656918

Group type: EXPERIMENTAL
Intervention: IGF-I 20 micrograms kg-1 h-1
Number of subjects: 6

Group type: COMPARATOR
Intervention: Insulin 0.5 mU kg-1 min-1
Number of subjects: 6
Study: 2679397

Group type: EXPERIMENTAL
Intervention: Allopurinol mouth wash (4-5 times daily before and after treatment)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no allopurinol mouth wash)
Number of subjects: 30
Study: 998545

Group type: EXPERIMENTAL
Intervention: Diets supplemented with lysine (1.8 g)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Diets without additional lysine (1.2 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diets with 100% or 50% replacement of amino acids from rice and wheat
Number of subjects: 6
Study: 31476260

Group type: EXPERIMENTAL
Intervention: Percutaneous valve repair plus medical treatment (n=152)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Medical treatment alone (n=152)
Number of subjects: 304
Study: 28712941

Group type: EXPERIMENTAL
Intervention: GP2013-CVP
Number of subjects: 629

Group type: COMPARATOR
Intervention: R-CVP
Number of subjects: 629
Study: 23569308

Group type: EXPERIMENTAL
Intervention: Docetaxel plus zibotentan 10 mg/d
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Docetaxel plus placebo
Number of subjects: 1052
Study: 21982143

Group type: EXPERIMENTAL
Intervention: Hospital-wide computerised antimicrobial approval system (HCAAS)
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: HCAAS
Number of subjects: 3500
Study: 18365222

Group type: EXPERIMENTAL
Intervention: Preoperative administration of 0.1 mg fentanyl + 5 ml bupivacaine 0.5%
Number of subjects: 564

Group type: COMPARATOR
Intervention: Postoperative administration of 0.1 mg fentanyl + 5 ml bupivacaine 0.5%
Number of subjects: 564

Group type: COMPARATOR
Intervention: Postoperative administration of 5 ml bupivacaine 0.5% alone
Number of subjects: 564
Study: 17803345

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 40 mg/day
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study: 15465069

Group type: EXPERIMENTAL
Intervention: Psychotherapy or antidepressant medications
Number of subjects: 14
Study: 11396760

Group type: EXPERIMENTAL
Intervention: Sclerotherapy with a 3% ethanolamine oleate solution (group 1, 18 patients)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Injection of tissue adhesive N-butyl-2-cyanoacrylate (group 2, 18 patients)
Number of subjects: 36
Study: 9849455

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus filgrastim
Number of subjects: 59

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 59
Study: 8006922

Group type: EXPERIMENTAL
Intervention: AHA type diet (32/10:8:8)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Monoene-enriched diet (34/11:11:5)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control diet (high in saturated fats) (35/14:10:4)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Low-fat diet (30/12:8:3)
Number of subjects: 160
Study: 2006655

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide or bendroflumethazide
Number of subjects: 1396

Group type: COMPARATOR
Intervention: Propranolol, nadolol, or captopril
Number of subjects: 1396
Study: 598635

Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 mg orally
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 mg sublingually
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate, 5 mg sublingually
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Propranolol, 40 mg orally
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo, 1 c. orally
Number of subjects: 5
Study: 31402145

Group type: EXPERIMENTAL
Intervention: Current malaria
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Inflammation (C-reactive protein >5 mg/L or α-1 acid glycoprotein >1 g/L)
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID)
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Vitamin A deficiency (retinol <0.7 μmol/L)
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Functional iron deficiency
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Anemia and ID in low malaria season
Number of subjects: 820
Study: 28870407

Group type: COMPARATOR
Intervention: D2/3 receptor availability in striatal regions (including bilateral ventral pallidum/nucleus accumbens, right ventral caudate, and putamen)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: D2/3 receptor availability in the caudal portion of the ventral striatum (NAc/vPAL)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: D2/3 receptor availability in the rostral area of the ventral striatum
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Baseline anxiety and D2/3 receptor availability in the NAc/vPAL
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Placebo-induced DA release in the bilateral NAc
Number of subjects: 23
Study: 26251413

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioural therapy (RAFT) delivered by local rheumatology clinical teams, consisting of 6 sessions of 2 hours each (weeks 1-6) and a 1-hour consolidation session (week 14).
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual care (fatigue self-management booklet, discussed for 5-6 minutes).
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioural therapy (RAFT).
Number of subjects: 64
Study: 23438931

Group type: EXPERIMENTAL
Intervention: Intensive dietary intervention of sodium reduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive dietary intervention of weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both sodium reduction and weight loss
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 0
Study: 22151943

Group type: EXPERIMENTAL
Intervention: Microneedling
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of microneedling and 35% GA peels
Number of subjects: 30

Group type: COMPARATOR
Intervention: Microneedling (Control Group)
Number of subjects: 30
Study: 19187557

Group type: EXPERIMENTAL
Intervention: Aquamin (2400 mg/d)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 16849756

Group type: EXPERIMENTAL
Intervention: Window therapy (various agents including ifosfamide, etoposide, doxorubicin, topoisomerase I poisons)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Ifosfamide/topoisomerase II inhibitor trials
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: IRS‐III and ifosfamide/etoposide and ifosfamide/doxorubicin trials
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Window nonresponders
Number of subjects: 420

Group type: COMPARATOR
Intervention: Window trials compared to IRS‐III
Number of subjects: 420
Study: 16154241

Group type: EXPERIMENTAL
Intervention: Aerosol measles vaccine (10(3.58) CCID50/0.1 mL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subcutaneous measles vaccine (10(4.28) CCID50/0.5 mL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aerosol measles vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subcutaneous measles vaccine
Number of subjects: 100
Study: 14562673

Group type: EXPERIMENTAL
Intervention: Tenax stent (a-SiC:H coated)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Nir stent (stainless steel)
Number of subjects: 497
Study: 10354255

Group type: EXPERIMENTAL
Intervention: Nurse standing orders with comparative feedback and patient and clinician reminders
Number of subjects: 3502

Group type: EXPERIMENTAL
Intervention: Nurse standing orders with compliance reminders and patient and clinician reminders
Number of subjects: 3502

Group type: COMPARATOR
Intervention: Patient and clinician reminders alone
Number of subjects: 3502
Study: 8573004

Group type: EXPERIMENTAL
Intervention: Thrice weekly dialysis (Kr = 0)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Twice weekly dialysis (nonzero Kr)
Number of subjects: 2
Study: 2197208

Group type: EXPERIMENTAL
Intervention: Operated group (n=51)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Nonoperated group (n=52)
Number of subjects: 103
Study: 7000233

Group type: EXPERIMENTAL
Intervention: Surgical intervention (gastric surgery)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 118
Study: 31466854

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg with carboplatin and etoposide
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo with carboplatin and etoposide
Number of subjects: 42
Study: 29550804

Group type: EXPERIMENTAL
Intervention: UCB transfusion (n = 5), administered once within 5 days of birth (mean 3.2 ± 1.9 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Allogeneic RBC transfusions (n = 15), administered 7.8 ± 3.9 days after birth
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: UCB transfusion (n = 5)
Number of subjects: 20
Study: 25886645

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) containing anti-JEV neutralizing antibody (ImmunoRel, 400mg/kg/day for 5 days)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 24156728

Group type: EXPERIMENTAL
Intervention: One titanium elastic nail (TEN)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Two titanium elastic nails (TENs)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 67
Study: 21257061

Group type: EXPERIMENTAL
Intervention: Ca-salts of fatty acids (CaFA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (2.9% DM as long-chain fatty acids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fat-supplemented diets (CaFA, SFA, TAG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saturated free fatty acids (SFA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triacylglyceride high in C16:0 fatty acids (TAG)
Number of subjects: 0
Study: 19074516

Group type: EXPERIMENTAL
Intervention: hsCRP >2.0 mg/L
Number of subjects: 4162

Group type: EXPERIMENTAL
Intervention: BNP >80 ng/L
Number of subjects: 4162

Group type: EXPERIMENTAL
Intervention: Both hsCRP and BNP increased
Number of subjects: 4162

Group type: COMPARATOR
Intervention: Intensive statin therapy
Number of subjects: 4162

Group type: EXPERIMENTAL
Intervention: hsCRP quartile Q4 vs Q1
Number of subjects: 4162

Group type: EXPERIMENTAL
Intervention: BNP quartile Q4 vs Q1
Number of subjects: 4162
Study: 16324780

Group type: EXPERIMENTAL
Intervention: 20,000 UI of lyophilized HAase (5 ml)
Number of subjects: 168
Study: 14998735

Group type: EXPERIMENTAL
Intervention: Cue-dose training (n = 16)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 79
Study: 11391327

Group type: EXPERIMENTAL
Intervention: Flutter device
Number of subjects: 40
Study: 9069614

Group type: EXPERIMENTAL
Intervention: Scalp cooling regimen (19 patients)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ambient temperature regimen (16 patients)
Number of subjects: 35
Study: 8275350

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (SCT) 200 IU
Number of subjects: 12
Study: 3553874

Group type: EXPERIMENTAL
Intervention: Influenza vaccine in elderly subjects (70% vaccinated)
Number of subjects: 691

Group type: COMPARATOR
Intervention: Influenza vaccine in younger subjects (50% vaccinated)
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Influenza vaccine in younger subjects
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Pre-existing antibody levels in elderly subjects
Number of subjects: 691
Study: 30919581

Group type: EXPERIMENTAL
Intervention: Oxygen saturations at time of discharge from stage‐I and stage‐II surgeries
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Oxygen saturation measurements below 80%
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Change in oxygen saturations over time
Number of subjects: 328
Study: 28886758

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate BAI 80 micrograms/day
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate BAI 160 micrograms/day
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate BAI 80 or 160 micrograms/day
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo BAI
Number of subjects: 270
Study: 26712779

Group type: EXPERIMENTAL
Intervention: Adolescents with normal Body Mass Index (BMI)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Adolescents classified as overweight
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Adolescents classified as obese
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Fathers classified as overweight or obese
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Mothers classified as overweight or obese
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Factors associated with adolescent overweight or obesity
Number of subjects: 816
Study: 24267258

Group type: EXPERIMENTAL
Intervention: HTE-DLP (Computerized Decision Support System)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: High potency statins and combined therapy
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Physician agreement and ease-of-use
Number of subjects: 77
Study: 21773992

Group type: EXPERIMENTAL
Intervention: PTH(1-84) 100 µg daily for 24 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: PTH(1-84)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 19435203

Group type: EXPERIMENTAL
Intervention: Mixed sorbent (microcellulose + polysorb) (6g), administered once a week, on average 20 days after operation.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned).
Number of subjects: 30
Study: 16712652

Group type: EXPERIMENTAL
Intervention: CHIT1 amino acid variants Gly102Ser and Ala442Gly
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: 24 bp duplication within CHIT1
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Haplotype analysis
Number of subjects: 322

Group type: COMPARATOR
Intervention: Adult controls
Number of subjects: 322
Study: 14697069

Group type: EXPERIMENTAL
Intervention: Hypercaloric diet (milk formula supplemented with 5% to 7% glucose polymers and 3% to 5% medium chain triglycerides)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal diet (milk formula only)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23
Study: 12195605

Group type: EXPERIMENTAL
Intervention: Fondaparinux (Arixtra TM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 0
Study: 9440758

Group type: EXPERIMENTAL
Intervention: ERCC1 mRNA levels less than or equal to 5.8 x 10(‐3)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: ERCC1 mRNA levels greater than 5.8 x 10(‐3)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both ERCC1 and TS mRNA levels below their medians
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both ERCC1 and TS mRNA levels above their medians
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: TS mRNA levels
Number of subjects: 38
Study: 8270988

Group type: EXPERIMENTAL
Intervention: Arm A: P 30 mg/m2 IV bolus followed by E 130 mg/m2 bolus
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Arm B: E 130 mg/m2 bolus followed by P 30 mg/m2 bolus
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Arm C: E 130 mg/m2 by 24-hour infusion and P 30 mg/m2 bolus at the end of each 24-hour infusion of E
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Arm D: E 130 mg/m2 by 24-hour infusion and P 45 mg/m2 by 24-hour infusion on day 2 and 3 only
Number of subjects: 552
Study: 2572797

Group type: EXPERIMENTAL
Intervention: L-tyrosine (9 g daily for 4 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 239966

Group type: EXPERIMENTAL
Intervention: Low dose practolol (1.5 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose practolol (12 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29649916

Group type: EXPERIMENTAL
Intervention: Breezhaler®
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ellipta®
Number of subjects: 100
Study: 28457097

Group type: EXPERIMENTAL
Intervention: Hévíz mud applied directly to both hands (n=23)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Nylon gloves separating the skin from the mud (n=24)
Number of subjects: 47
Study: 26048068

Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 64
Study: 23504930

Group type: EXPERIMENTAL
Intervention: Short-term hormone therapy (futamide plus a luteinizing hormone-releasing hormone agonist for 4 months)
Number of subjects: 1070
Study: 22365398

Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide (Al‐OH) adjuvant
Number of subjects: 0

Group type: COMPARATOR
Intervention: No aluminum hydroxide (placebo)
Number of subjects: 0
Study: 19351542

Group type: EXPERIMENTAL
Intervention: Intra-articular Botulinum Toxin Type A (IA-BoNT/A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: IA-BoNT/A
Number of subjects: 0
Study: 16643222

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 70
Study: 14566568

Group type: EXPERIMENTAL
Intervention: Glucose ingested 30 min before exercise (50 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucose ingested during exercise (110 g or 160 g in fractionated doses)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucose ingested both before and during exercise (50 g before and 110 g during)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo or unlabelled glucose ingested during exercise
Number of subjects: 6
Study: 11209991

Group type: EXPERIMENTAL
Intervention: Low-intensity primary care-based intervention to prevent depression relapse, including education about depression, motivation-enhancing shared decision-making, and cognitive-behavioral strategies.
Number of subjects: 194
Study: 8770969

Group type: EXPERIMENTAL
Intervention: Sirolimus (1 to 3 mg/m2/day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sirolimus (5 to 6 mg/m2/day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sirolimus (7 to 13 mg/m2/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (0 mg/m2/day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sirolimus (any dose)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (CsA/corticosteroid regimen)
Number of subjects: 70